SCHEMBL2446906

SCHEMBL2446906

COc1ccc(C(=O)NN)cc1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.63
CYP3A4 P08684 1/20 0.63
CYP2C9 P11712 1/20 0.63
TSHR P16473 1/20 0.63
CYP2C19 P33261 1/20 0.63
CA1 P00915 2/20 0.61
CA2 P00918 2/20 0.61
CA12 O43570 1/20 0.61
CA4 P22748 1/20 0.61
CA6 P23280 1/20 0.61
CA7 P43166 1/20 0.61
TPMT P51580 1/20 0.61
CA9 Q16790 1/20 0.61
CA14 Q9ULX7 1/20 0.61
MAPT P10636 5/20 0.59
MAPK1 P28482 2/20 0.59
ALOX15 P16050 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
NR1H4 Q96RI1 1/20 0.59
HDAC3 O15379 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29412632 1.00 CYP1A2 (0.63) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL19988183 0.86 FLT3 (0.53) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL15573157 0.86 ALDH1A1 (0.64) SMN1; SMN2NR1H4KMT2AMEN1ALDH1A1
SCHEMBL20328602 0.86 TP53 (0.52) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL6511696 0.86 TAS1R3 (0.65) CYP1A2CYP3A4CYP2C9CYP2C19CA1
SCHEMBL966735 0.86 CTSD (0.62) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL5678411 0.86 CA1 (0.56) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL4162113 0.86 PDE4D (0.58) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL11328691 0.86 ALDH1A1 (0.69) CYP1A2CYP3A4CYP2C9CYP2C19CA1
SCHEMBL12937578 0.86 TAS1R3 (0.58) CYP1A2CYP3A4CYP2C9TSHRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103130766-B Piperine hydrazone or acylhydrazone or sulfonyl hydrazone derivative substances and application for preparing a botanical insecticide UNIV NORTHWEST A&F 2014-06-11 CN claimed
CN-103130766-A Piperine hydrazone or acylhydrazone or sulfonyl hydrazone derivative substances and application for preparing a botanical insecticide UNIV NORTHWEST A&F 2013-06-05 CN claimed
US-8193168-B2 Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release REDPOINT BIO CORPORATION (US) 2012-06-05 US claimed
EP-2107908-A2 USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 RELEASE Redpoint Bio Corporation (US) 2009-10-14 EP claimed
US-20080306030-A1 Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release REDPOINT BIO CORPORATION (US) 2008-12-11 US claimed
WO-2008097504-A2 USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 RELEASE REDPOINT BIO CORPORATION (US) 2008-08-14 WO claimed
US-20030105140-A1 Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. 2003-06-05 US claimed
WO-2002102301-A2 SUBSTITUTED INDOLE-2-CARBOXYLIC ACID BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA, INC. (US) 2002-12-27 WO claimed
US-20020128292-A1 Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. 2002-09-12 US claimed
US-20250346588-A1 IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS KUDA THERAPEUTICS INC (US) 2025-11-13 US disclosed
US-12275711-B2 Compounds having excited state intramolecular proton transfer (ESIPT) character for use in treating and/or preventing sunburn and/or preventing U.V. damage UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG (ZA) 2025-04-15 US disclosed
US-11731934-B2 HDAC inhibitor compounds and methods of treatment UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2023-08-22 US disclosed
EP-4204401-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2023-07-05 EP disclosed
CN-116323558-A Compounds and methods for treating diseases 艾特里提治疗有限公司 2023-06-23 CN disclosed
EP-0566446-A1 Derivatives of indane-1,3-dione and indane-1,2,3-trione, processes for their preparation and their application in therapy INNOTHERA (FR) 1993-10-20 EP disclosed
WO-1993020046-A1 INDAN-1,3-DIONE AND INDAN-1,2,3-TRIONE DERIVATIVES, PROCESSES FOR PREPARATION OF SAME AND THEIR USE AS THERAPEUTIC AGENTS INNOTHERA (FR) 1993-10-14 WO disclosed
US-5173492-A Bronchodilator agents KYOWA HAKKO KOGYO CO., LTD. (JP) 1992-12-22 US disclosed
EP-0417790-A2 S-triazolo[3,4-i]purine derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 1991-03-20 EP disclosed
US-4642322-A Stabilization of chlorine-containing thermoplastics with nitrogen-containing organic compounds CIBA-GEIGY CORPORATION (US) 1987-02-10 US disclosed
US-4279982-A PRINTOUTS; OXADIAZOLE PHOTOINITIATORS FUJI PHOTO FILM CO., LTD. (JP) 1981-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12275711-B2 Compounds having excited state intramolecular proton transfer (ESIPT) character for use in treating and/or preventing sunburn and/or preventing U.V. damage NNT, NQO1, SUN2 CYP1A2 2806/4885CYP3A4 2021/4885CYP2C9 1696/4885
US-20020128292-A1 Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof BAD, API5, CASP2 CYP1A2 502/4885CYP3A4 1159/4885CYP2C9 2082/4885
US-20030105140-A1 Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof BAD, API5, CASP2 CYP1A2 502/4885CYP3A4 1159/4885CYP2C9 2082/4885
US-20250346588-A1 IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS HIF1AN, HIF1A, EGLN2 CYP1A2 479/4885CYP3A4 1238/4885CYP2C9 2234/4885
US-11731934-B2 HDAC inhibitor compounds and methods of treatment HDAC4, HDAC1, HDAC5 CYP1A2 4109/4885CYP3A4 4169/4885CYP2C9 4792/4885
US-20080306030-A1 Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release GLP1R, GIPR, TRPM5 CYP1A2 4676/4885CYP3A4 3813/4885CYP2C9 3985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.